Editorial

Should You Register Your Study as a Clinical Trial?
Governments and international organizations have been working steadily to make clinical trial information more transparent and widely available and to standardize registries and processes of registering. I' d like to briefl y discuss which studies should be registered, the reasons why registration is important, and some remaining issues of debate.
A clinical trials registry is a publicly available, sanctioned site for registering a clinical trial. Th e most widely used registry is ClinicalTrials.gov (access https://clinicaltrials. gov), which is maintained by the U.S. Importantly, many more studies now qualify for registry since the NIH (2014) broadened its defi nition of a clinical trial to: "A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the eff ects of those interventions on health-related biomedical or behavioral outcomes" (para. 4). Th is highly inclusive defi nition does not require random allocation to study conditions, the use of a control group, or the estimation of a required sample size suffi cient to avoid a Type II error. Hence, within this defi nition, many pilot studies, feasibility studies, and studies that use a pretest-posttest design without a control or comparison group should be registered. Th e World Health Organization's (2019) defi nition of clinical trials is used by the ICMJE and is as broad and inclusive as the NIH defi nition.
Th ere are scientifi c, ethical, and clinical reasons why registration is important. Registration helps eliminate publication biases, as the results of only 50% of trials are ever published (Jones, 2013) . One review found that trial results, especially serious adverse events, are more completely reported at ClinicalTrials.gov than in the published article (Riveros et al., 2013) . Clinicians and public policymakers require complete and accurate information regarding the effi cacy and adverse eff ects of interventions.
Requirements regarding prospective registration of trials can mitigate suppression of outcomes that do not support effi cacy or changing hypotheses based on results obtained. A systematic review of 22 analyses for selective outcome reporting found that 40% to 62% of studies had at least one primary outcome changed, added, or omitted from protocol to publication (Dwan, Gamble, Williamson, & Kirkham, 2013) . Another study of 21 trials published in Th e BMJ found that 27% (89/333) of outcomes prespecifi ed in the protocol were not reported in the manuscript, and 11% (31/275) of reported outcomes were not prespecifi ed (Weston et al., 2016) . Scientists who perform metaanalyses and other systematic reviews can only provide accurate summaries of fi ndings when positive and negative results are accessible. Providing the questions to be studied and the key aspects of the study methodology in the registry can inform other researchers of ongoing work and methods being used and possibly prevent some duplication of eff orts. From an ethical point of view, registries support international scientifi c cooperation, provide global access to cutting-edge research, increase a patient's ability to learn of new experimental studies accepting participants, and provide opportunities to evaluate adherence to scientifi c and ethical standards.
Several reports of prospective and retrospective registration have shown that many clinical trials are never registered or are registered aft er participants have been enrolled (Harriman & Patel, 2016; Huser & Cimino, 2013; Scott, Rucklidge, & Mulder, 2015) . A review of randomized controlled trials published in three nursing journals between 2011 and 2016 found that 58% were not registered and only 8% met criteria for timely registration (Gray et al., 2017) . Trials not registered before enrolling participants are by defi nition less transparent and decrease confi dence that amendments to the protocol, hypotheses, and outcomes have been adequately reported.
Registration of a study provides no determination of quality or even that a rigorous clinical trial design has been used. In addition to issues of quality, a remaining concern is the broad nature of what is included as a clinical trial. Although the relatively new defi nition of a clinical trial was not intended to expand the scope of the category of clinical trials, the defi nition does not specifi cally require randomization or a control group. Studies that are one-group comparisons from pre-to posttest qualify as clinical trials if the principal investigator can answer "yes" to these four questions (NIH, 2018, para. 3):
1. Does the study involve human participants? 2. Are the participants prospectively assigned to an intervention?
3. Is the study designed to evaluate the eff ect of the intervention on the participants? 4. Is the eff ect being evaluated a health-related biomedical or behavioral outcome?
Small feasibility studies and pilot studies may meet the criteria for registration under the NIH defi nition of a clinical trial. Th ese studies are oft en used primarily to demonstrate to proposal reviewers that methods planned for a large clinical trial are rigorous and feasible, but they also oft en include some measurement of the eff ects of an intervention. Th ese studies are oft en not adequately powered and do not use randomization and other control strategies to protect internal validity. If the primary purpose of these studies is to sort out methods, the need for registration is unclear. Including these preliminary studies in translational work and systematic reviews could distort conclusions.
In our list of author submission guidelines, Research in Gerontological Nursing (RGN) states that we follow ICMJE guidelines. At this point, we report all submitted registrations and require registration of all intervention studies with randomization to study conditions that are not classifi ed as pilot or feasibility studies. We will continue to evaluate this policy as the momentum of current discussions is favoring expanded requirements for registering trials and reporting results of clinical trials. Th e ICMJE (2016) suggests that if researchers are uncertain whether their study meets the defi nition for a clinical trial, they should err on the side of registration. We encourage all authors submitting intervention studies to RGN to report positive and negative fi ndings as well as any adverse events. Transparent reporting of research benefi ts clinicians, scientists, patients, and public policymakers.
